KalVista Pharmaceuticals Inc Stock News

KalVista Pharmaceuticals (NASDAQ:KALV) had its price objective lowered by Needham & Company LLC from $50.00 to $48.00 in a research note published on Friday morning, Stock Target Advisor reports. The firm currently has a buy rating on the specialty pharmaceutical companys stock. Several other brokerages have also weighed in on KALV. Zacks Investment Research upgraded []

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has been given a consensus rating of Buy by the seven analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a []

KalVista Pharmaceuticals (NASDAQ:KALV) issued its earnings results on Wednesday. The specialty pharmaceutical company reported ($0.80) EPS for the quarter, missing analysts consensus estimates of ($0.79) by ($0.01), Fidelity Earnings reports. Shares of NASDAQ:KALV opened at $13.73 on Friday. The businesss fifty day moving average price is $16.79 and its two-hundred day moving average price is []

KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q2 earnings results on Thursday, December 9, 2021 at 06:30 AM. Here's what investors need to know about the announcement.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2021. This quarter we made great strides in advancing the two distinct compounds in our oral hereditary angioedema franchise into later sta

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has earned a consensus recommendation of Buy from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the []

Goldman Sachs Group Inc. reduced its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 42.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,610 shares of the specialty pharmaceutical companys stock after selling 22,989 shares during the period. Goldman Sachs []

Metropolitan Life Insurance Co NY boosted its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 100,660.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,038 shares of the specialty pharmaceutical companys stock after buying an additional 5,033 []

Marshall Wace LLP decreased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 54.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,996 shares of the specialty pharmaceutical companys stock after selling 20,447 shares during the period. Marshall Wace LLP owned []

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has earned an average rating of Buy from the seven analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokers that have []

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializat

CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commerc

The FDA has lifted the clinical hold on KalVista Pharmaceuticals Inc's (NASDAQ: KALV) Phase 2 trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE). Related Content:   Ka